Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road
Bashkim Kadriu, Laura Musazzi, Jenessa N. Johnston, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 12, pp. 2816-2838
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 48
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
Dysfunctional serotonergic neuron-astrocyte signaling in depressive-like states
Candela González-Arias, Andrea Sánchez-Ruiz, Julio Esparza, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3856-3873
Open Access | Times Cited: 37
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
John H. Krystal, Alfred P. Kaye, Sarah Jefferson, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 30
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Josh Allen, Shannon Dames, Claire J. Foldi, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 3, pp. 671-685
Closed Access | Times Cited: 13
AMPA receptors play an important role in the biological consequences of spinal cord injury: Implications for AMPA receptor modulators for therapeutic benefit
Jeffrey M. Witkin, Daniel P. Radin, Sabhya Rana, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116302-116302
Closed Access | Times Cited: 8
NaV1.1 haploinsufficiency impairs glutamatergic and GABAergic neuron function in the thalamus
Carleigh Studtmann, Marek Ladislav, Mackenzie A. Topolski, et al.
Neurobiology of Disease (2022) Vol. 167, pp. 105672-105672
Open Access | Times Cited: 28
Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant
Atsushi Suzuki, Hiroe Hara, Haruhide Kimura
Neuropharmacology (2022) Vol. 222, pp. 109308-109308
Open Access | Times Cited: 27
Plasticity of synapses and reward circuit function in the genesis and treatment of depression
Scott M. Thompson
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 90-103
Closed Access | Times Cited: 23
Clinical pharmacological innovation in the treatment of depression
Jeffrey M. Witkin, Lalit K. Golani, Jodi L. Smith
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 349-362
Closed Access | Times Cited: 13
Revolutionizing Neurological Disorder Treatment: Integrating Innovations in Pharmaceutical Interventions and Advanced Therapeutic Technologies
Rimpi Arora, Ashish Baldi
Current Pharmaceutical Design (2024) Vol. 30, Iss. 19, pp. 1459-1471
Closed Access | Times Cited: 5
Synthesis and modulatory activity of 3-acetyl-7-(benzofuran-5-carbonyl)-1,5-dimethyl-3,7-diazabicyclo[3.3.1]nonan-9-one on AMPA receptors
J. L. Matthews, Polina N. Veremeeva, Elena A. Golubeva, et al.
Chemistry of Heterocyclic Compounds (2025)
Closed Access
Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today
Daniel P. Radin, Arnold S. Lippa, Sabhya Rana, et al.
Pharmacology Biochemistry and Behavior (2025) Vol. 248, pp. 173967-173967
Closed Access
The severity of SLC1A2-associated neurodevelopmental disorders correlates with transporter dysfunction
Peter Kovermann, Allan Bayat, Christina Fenger, et al.
EBioMedicine (2025) Vol. 114, pp. 105648-105648
Open Access
Diversity of AMPA Receptor Ligands: Chemotypes, Binding Modes, Mechanisms of Action, and Therapeutic Effects
Elena A. Golubeva, Mstislav I. Lavrov, Eugene V. Radchenko, et al.
Biomolecules (2022) Vol. 13, Iss. 1, pp. 56-56
Open Access | Times Cited: 20
Enhanced TARP-γ8-PSD-95 coupling in excitatory neurons contributes to the rapid antidepressant-like action of ketamine in male mice
Shi-Ge Xue, Jin‐Gang He, Lingli Lu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Dysfunction of Glutamatergic Synaptic Transmission in Depression: Focus on AMPA Receptor Trafficking
Jin‐Gang He, Hai-Yun Zhou, Fang Wang, et al.
Biological Psychiatry Global Open Science (2022) Vol. 3, Iss. 2, pp. 187-196
Open Access | Times Cited: 17
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
Andrzej Pilc, Agata Machaczka, Paweł Kawalec, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 10, pp. 1131-1146
Closed Access | Times Cited: 17
Novel α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor (AMPAR) potentiator LT‐102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia
Xueyu Qi, Xueli Yu, Wei Long, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 4
Open Access | Times Cited: 3
The PrLGlu→avBNSTGABA circuit rapidly modulates depression-like behaviors in male mice
J Chen, Ke Wu, Miaomiao Guo, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107878-107878
Open Access | Times Cited: 7
3,4-Dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide analogs act as potential AMPA receptor potentiators with antidepressant activity
Long wei, Xueyu Qi, Xueli Yu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 251, pp. 115252-115252
Closed Access | Times Cited: 6
TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats
Hiroe Hara, Atsushi Suzuki, Akiyoshi Kunugi, et al.
Pharmacology Biochemistry and Behavior (2021) Vol. 211, pp. 173289-173289
Open Access | Times Cited: 13
New Allosteric Modulators of AMPA Receptors: Synthesis and Study of Their Functional Activity by Radioligand-Receptor Binding Analysis
Elena A. Golubeva, Mstislav I. Lavrov, Polina N. Veremeeva, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10293-10293
Open Access | Times Cited: 4
Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice
Yonglei Du, Feng Gao, Hong‐Wei Sun, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115855-115855
Closed Access | Times Cited: 4
MSK1 is required for the experience- and ampakine-dependent enhancement of spatial reference memory and reversal learning and for the induction of Arc and BDNF
Lorenzo Morè, Lucia Privitera, Márcia Marília Gomes Dantas Lopes, et al.
Neuropharmacology (2024) Vol. 261, pp. 110110-110110
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top